Treatment of cytomegalovirus infection

E. C. Reed, J. D. Meyers

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

Passive immunotherapy with high doses of pooled unscreened immunoglobulins or immunoglobulin specifically prepared from donors with high levels of antibody to CMV has few adverse side-effects and is succesful in producing good increments in CMV antibody levels. The conflicting results of treatment trials and the lack of a demonstrated antiviral effect in vivo do not encourage the use of immunoglobulin alone for the treatment of CMV disease. The prophylactic effectiveness of immunoglobulin for CMV disease in seronegative marrow transplant patients is also questionable, although there is some indication that prophylaxis in patients with less severe immune defects (for example, renal transplant patients) may be useful.

Original languageEnglish (US)
Pages (from-to)831-852
Number of pages22
JournalClinics in Laboratory Medicine
Volume7
Issue number4
StatePublished - Dec 1 1987

    Fingerprint

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this